Investigation and Exploitation of Antibody Combining Sites von Eric Reid | ISBN 9781468450088

Investigation and Exploitation of Antibody Combining Sites

von Eric Reid, G.M.W. Cook und D.J. Morre
Mitwirkende
Autor / AutorinEric Reid
Autor / AutorinG.M.W. Cook
Autor / AutorinD.J. Morre
Buchcover Investigation and Exploitation of Antibody Combining Sites | Eric Reid | EAN 9781468450088 | ISBN 1-4684-5008-5 | ISBN 978-1-4684-5008-8

Investigation and Exploitation of Antibody Combining Sites

von Eric Reid, G.M.W. Cook und D.J. Morre
Mitwirkende
Autor / AutorinEric Reid
Autor / AutorinG.M.W. Cook
Autor / AutorinD.J. Morre

Inhaltsverzeichnis

  • #A Antibody Combining Sites, Especially Structure.
  • #A–1 Antibody combining sites — past, present and future.
  • #A–2 Variability, modelling and prediction of ?-hairpins with reference to the immunoglobulin fold.
  • #A–3 Probing the binding sites in crystals of immunoglobulins.
  • #A–4 Comparative structures of mouse antibody combining sites.
  • #NC(A) NOTE and COMMENTS related to the foregoing topics*.
  • #NC(A)–1 An approach to the study of anti-protein antibody combining sites.
  • #B Production and Characterization of Antibodies, in Contexts such as Receptor Investigation.
  • #B–1 Investigating the specificity of monoclonal antibodies to protein antigens using ?-galactosidase fusion proteins.
  • #B–2 Antibody-screening cDNA libraries.
  • #B–3 Anti-receptor antibodies by the auto-anti-idiotypic route.
  • #B–4 Production and characterization of anti-morphine anti-idiotypic antibodies.
  • #B–5 Anti-idiotype antibodies for the study of membrane receptors: the double monoclonal antibody approach.
  • #NC(B) NOTES and COMMENTS related to the foregoing topics.
  • #NC(B)–1 Characterization of idiotypes and VH genes of various members of A48-idiotypic network pathway.
  • #NC(B)–2 Monoclonal internal image anti-idiotypic antibodies of hepatitis B surface antigen.
  • #NC(B)–3 Structure and expression of genes encoding IgA heavy chains.
  • #NC(B)–4 Human: mouse antibody-producing transfectoma cell lines.
  • #NC(B)–5 Different ways to modify monoclonal antibodies.
  • #NC(B)–6 Restructuring enzymes and antibodies.
  • #NC(B)–7 Dideoxy mRNA sequencing as a method to analyze antibody diversity.
  • #NC(B)–8 Effect of multivalent binding on dissociation of monoclonal antibodies from cell surface antigens.
  • #C Cytoskeletal, Myocyte and Neuronal Studies with Antibodies.
  • #C–1Immunological approaches and techniques employed in tubulin and microtubule research.
  • #C–2 Cell-surface events during myogenesis: immunofluorescence analysis using monoclonal antibodies.
  • #C–3 Differential expression of cell-surface antigens on muscle satellite cells and myoblasts.
  • #C–4 Cholinergic-specific nerve terminal antigens.
  • #C–5 Use of antibodies to purify cholinergic nerve terminals.
  • #NC(C) NOTES and COMMENTS related to the foregoing topics.
  • #NC(C)–1 An immunological approach to the cell lineage problem in the mammalian CNS.
  • #NC(C)–2 An enzyme-linked immunosorbent assay for calmodulin.
  • #NC(C)–3 Intermediate filament diversity as detected by antibodies.
  • #D Antibody Approaches to Membrane Components Including the T-Cell Receptor.
  • #D–1 Exploitation of antibodies in the study of cell membranes.
  • #D–2 Use of polyclonal and monoclonal antibodies in studying complement component C9 as a transmembrane protein.
  • #D–3 Ca2+-binding proteins located on the cytoplasmic face of the lymphocyte plasma membrane.
  • #D–4 The T-cell receptor.
  • #NC(D) NOTES and COMMENTS related to the foregoing topics.
  • #NC(D)–1 New light on the T-cell receptor in relation to antibody binding sites.
  • #NC(D)–2 Molecular nature of the T3 antigen of human T lymphocytes.
  • #NC(D)–3 Organization and expression of the murine T-cell receptor ?-chain gene complex.
  • #NC(D)–4 Antigen-specific T-cell activation.
  • #E Antibodies in Relation to Oncology.
  • #E–1 Requirements by cancer cells for polypeptide growth factors suggest new therapeutic strategies.
  • #E–2 Monoclonal antibodies to human tumours for targeting cytotoxic drugs.
  • #E–3 Antigenic modulation as a limiting factor in the treatment of B-cell lymphoma with anti-idiotype antibody.
  • #E–4 Tumour-associatedcarbohydrate antigens of glycoproteins.
  • #E–5 Glycolipid antigens: potential in cancer detection and diagnosis.
  • #NC(E) NOTES and COMMENTS related to the foregoing topics.
  • #NC(E)–1 Immune surveillance.
  • #NC(E)–2 WORKSHOP DISCUSSION focused on #E–4, #E–5 & #E–3.
  • Guidance for ‘uninitiated’ readers.
  • Corrections to Vol. 13.